Ramière C, Charre C, Miailhes P, et al. Patterns of hepatitis C virus transmission in human immunodeficiency virus (HIV)-infected and HIV-negative men who have sex with men. C Infect Dis 69; 2127-35, 2019.
Bartlett SR, Wertheim JO, Bull RA, et al. A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies. J Viral Hepat. 24:404-11. 2017.
Centers for Disease Control and Prevention. Sexual Transmission of Hepatitis C Virus Among HIV-Infected Men Who Have Sex with Men - New York City, 2005-2010. Morb Mortal Wkly Rep. 60:945-50. 2011.
Foster AL, Gaisa MM, Hijdra RM, et al. Shedding of hepatitis C virus into the rectum of HIV-infected men who have sex with men. Clin Infect Dis. 64:284-88. 2016.
Nishijima T, Shimbo T, Komatsu H, et al. Incidence and risk factors for incident hepatitis C infection among men who have sex with men with HIV-1 infection in a large urban HIV clinic in Tokyo. J Acquir Immune Defic Syndr. 65(2):213-7. 2014.
Nguyen T, Delaugerre C, Valantin MA, et al. Shared HCV transmission networks among HIV-1-positive and HIV-1-negative men having sex with men by ultradeep sequencing. J AIDS 82; 105-110, 2019.
Irvin R, Gamble T, Malone J, et al. HPTN 078: High Prevalence of HCV Antibodies Among Urban U.S. Men Who Have Sex with Men (MSM) Independent of HIV Status. Clin Infect Dis. 2020 Dec 21: ciaa1869. doi: 10.1093/cid/ciaa1869. Online ahead of print.
Koike K, Tsukada K, Yotsuyanagi H, et al. Prevalence of coinfection with human immunodeficiency virus and hepatitis C virus in Japan. Hepatol Res. 37:2-5. 2007.
Tatsunami S, Mimaya J, Shirahata A, et al. Current status of Japanese HIV-infected patients with coagulation disorders: coinfection with both HIV and HCV. Int J Hematol. 88:304-10. 2008.
Marco A, Esteban JI, Solé C, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol. 59:45-51. 2013.
Lambers FA, Prins M, Thomas X, et al. Alarming incidence of HCV re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV MSM. AIDS. 25:F21-7. 2011.
Sarrazin C, Isakovv V, Svarovskaia ES, et al. Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies. Clin Infect Dis. 64:44-52. 2017.
Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 13:34-41. 2006.
Danta M, Semmo N, Fabris P, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis. 197:1558-66. 2008.
Dionne-Odom J, Osborn MK, Radziewicz H, et al. Acute hepatitis C and HIV coinfection. Lancet Infect Dis. 9:775-83. 2009.
Kim AY, Schulze zur Wiesch J, Kuntzen T, et al. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med. 3:e492. 2006.
Kokordelis P, Krämer B, Körner C, et al. An effective interferon-gamma mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus-positive patients. Hepatology. 59:814-27. 2014.
Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 48:418-31. 2008.
Stenkvist J, Nyström J, Falconer K, et al. Occasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals. J Hepatol. 61:957-61. 2014.
Vispo E, Barreiro P, Plaza Z, et al. Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy. AIDS. 28:1473-8. 2014.
Fujinaga H, Tsutsumi T, Yotsuyanagi H, et al. Hepatocarcinogenesis in Hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species. Oncology. 81(suppl 1): 11-17. 2011.
McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 43:365-72. 2006.
Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol. 44:1026-32. 2006.
Kim AY, Lauer GM, Ouchi K, et al. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T cell count in individuals coinfected with HIV-1. Blood. 105:1170-8. 2005.
Pembroke T, Deschenes M, Lebouché B, et al. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. J Hepatol. 67:801-8. 2017.
Woreta TA, Sutcliffe CG, Mehta SH, et al. Incidence and Risk Factors for Steatosis Progression in Adults Coinfected With HIV and Hepatitis C Virus. Gastroenterology. 140:809-17. 2011.
Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 30:1054-8. 1999.
Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 21:2209-16. 2007.
Martinez-Sierra C, Arizcorreta A, Díaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis.36:491-8. 2003.
Terrier B, Carrat F, Geri G, et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol. 55:756-61.2011.
Lin W, Weinberg EM, Tai AW, et al. HIV increases HCV replication in a TGF-β1-dependent manner. Gastroenterology. 134: 803-11. 2008.
Tuyama AC, Hong F, Saiman Y, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/ hepatitis C virus-induced liver fibrosis. Hepatology. 52: 612-22. 2010.
Seki E, Minicis S, österreicher C, et al. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med.13: 1324-32. 2007.
Lidofsky A, Holmes JA, Feeney ER, et al. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis. 218:1394-1403. 2018.
Chen X, Liu X, Duan S, et al. Plasma Inflammatory Biomarkers Associated with Advanced Liver Fibrosis in HIV-HCV-Coinfected Individuals. Int J Environ Res Public Health. 17:9474, 2020.
Franco S, Buccione D, Tural C, et al. Circulating microRNA signatures that predict liver fibrosis progression in patients with HIV-1/hepatitis C virus coinfections. AIDS.35(9):1355-1363. 2021.
Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, et al. North American AIDS Cohort Collaboration on Research and Design of IeDEA. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open. 2021 ;4(2): 2020.
Bräu N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U. S.-Canadian multicenter study. J Hepatol. 47:527-37. 2007.
Salmon D, Bani-Sadr F, Loko MA, et al. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: Results from ANRS CO13 HEPAVIH. J Hepatol. 56:862-8. 2012.
Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis.33:240-7. 2001.
Yoo TW, Donfield S, Lail A, et al. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis. 191:4-10. 2005.
Daar ES, Lynn H, Donfield S, et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis. 183:589-95. 2001.
Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 36:363-7. 2003.
Cacoub P, Geffray L, Rosenthal E, et al. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis. 32:1207-14. 2001.
Haydon GH, Flegg PJ, Blair CS, et al. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Eur J Gastroenterol Hepatol.10:485-9. 1998.
Sulkowski MS, Moore RD, Mehta SH, et al. Hepatitis C and progression of HIV disease. JAMA. 288:199-206. 2002.
Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 192:992-1002. 2005.
Kovari H, Rauch A, Kouyos R, et al. Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study. Clin Infect Dis. 64:490-7. 2016.
Meijide H, Pertega S, Rodríguez-Osorio I, et al. Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected. AIDS. 31:1099-107. 2017.
Alejos B, Hernando V, Iribarren J, et al. Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: Role of HCV coinfection. Medicine (Baltimore). 95: e4727. 2016.
Tan BK, Chalouni M, Ceron DS, et al. Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus. Clin Infect Dis. 2020 Jul 20:ciaa1014. doi: 10.1093/cid/ciaa1014. Online ahead of print.
Carrero A, Berenguer J, Hontañón V, et al. Effects of HCV Eradication on Bone mineral density in HIV/HCV Coinfected Patients. Clin Infect Dis. 2020 Sep 15:ciaa1396. doi: 10.1093/cid/ciaa1396. Online ahead of print.
H Al-Mohri, T Murphy, Y Lu, et al. Evaluating Liver Fibrosis Progression and the Impact of Antiretroviral Therapy in HIV and Hepatitis C Coinfection Using a Noninvasive Marker. J Acquir Immune Defic Syndr. 44:463-9. 2007.
Macías J,Girón-González JA, González-Serrano M, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut. 55:409-14. 2006.
Sánchez-Conde M, Montes-Ramírez ML, Miralles P, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat. 17:280-6. 2010.
Sánchez-Conde M, Miralles P, BellEón JM, et al. Use of transient elastography (FibroScan) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients. J Viral Hepat. 18:685-91. 2011.
Ichikawa S, et al. Magnetic Resonance Elastography for Staging Liver Fibrosis in Chronic Hepatitis C. Magn Reson Med Sci. 2013; 11: 291-97.
Sherman, KE, Abdel-Hameed, EA, Ehman, RL, Rouster, SD, Campa, A, Martinez, SS, Huang, Y, Zarini, GG, Hernandez, J, et al. Validation and Refinement of Noninvasive Methods to Assess Hepatic Fibrosis: Magnetic Resonance Elastography Versus Enhanced Liver Fibrosis Index. Dig Dis Sci 2019. https://link.springer.com/article/10.1007/s10620-019-05815-z
Okanoue T, Itoh Y, Minami M, et al. Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Hepatol Res. 38:27-36. 2008.
Maida I, Soriano V, Barreiro P, et al. Liver fibrosis stage and HCV genotype distribution in HIV-HCV co-infected patients with persistently normal transaminases. AIDS Res Hum Retroviruses. 23:801-4. 2007.
Uberti-Foppa C, De Bona A, Galli L, et al. Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels. J Acquir Immune Defic Syndr. 41:63-7. 2006.
Quinn JR, Goyal A, Ribeiro RM, et al. Antiretroviral therapy for HIV and intrahepatic hepatitis C virus replication. AIDS. doi: 10.1097/QAD.0000000000003116. Epub ahead of print. PMID: 34690280. 2021.
Thein HH, Yi Q, Dore GJ, and Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis. AIDS. 22:1979-91. 2008.
Bräu N, Salvatore M, Ríos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 44: 47-55. 2006.
Sterling RK, Wegelin JA, Smith PG, et al. Similar progression of fibrosis between HIV/HCV-infected and HCV- infected patients: analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol. 8: 1070-6. 2010.
Benhamou Y, DeMartinio V, Bochet M, et al. factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus co-infected patients: impact of protease inhibitor therapy. Hepatology. 34:283-7. 2001.
Kramer JR, Giordano TP, Souchek J, et al. The effect of HIV co-infection on the risk of cirrhosis and hepatocellular carcinoma. In U.S. veterans with hepatitis C. Am J Gastroenterol. 100:56-63. 2005.
Bräu N, Salvatore M, Ríos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 44:47-55. 2006.
Klein MB, Althoff KN, Jing Y, et al. Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis. 63: 1160-7. 2016.
Qurishi N, Kleuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 362:1708-13. 2003.
Ragni MV, Nalesnik MA, Schillo R, et al. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection. Haemophilia. 15:552-8. 2009.
Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 36: 363-7. 2003.
Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology.41: 123-31. 2005.
Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 283:74-80. 2000.
Montaner JS, Hogg R, Raboud J, et al. Antiretroviral treatment in 1998. Lancet. 352:1919-22. 1998.
Martinez E, Gatell J. Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet. 352:821-2. 1998.
Brunet L, Moodie EE, Young J, et al. Progression of liver fibrosis and modern combination antiretroviral therapy regimens in HIV-hepatitis C-coinfected persons. Clin Infect Dis. 62: 242-9. 2016.
Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C co-infection. Clin Infect Dis. 38(suppl 2): S104-S108. 2004.
Atranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 40: 588-93. 2005.
Avidan NU, Goldstein D, Rozenberg L, et al. Hepatitis C viral kinetics during treatment with Peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. J Acquir Immune Defic Syndr. 52: 452-8. 2009.
Rozera G, FabbriG, Lorenzini P, et al. Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals. Plos one.12(10):e0187095. 2017.
Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 15: 645-53. 2015.
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 370: 1889-98. 2014.
Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-88. 2014.
Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 370: 1483-93. 2014.
Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 313: 1232-9. 2015.
Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 373: 705-13. 2015.
Nagao A, Hanabusa H. The impact of ledipasvir/sofosbuvir on HIV-positive and HIV-negative Japanese hemophilia patients with 1, 4, and mixed-genotype HCV. J Acquir Immune Defic Syndr. 74:418-22. 2016.
Uemura H, Tsukada K, Mizushima D, et al. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders. Plos one. 12 (10) e0186255. 2017.
Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 385:1087-97. 2015.
Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO -INFECTION): a non-randomised, open-label trial. Lancet HIV. 2: e319-27. 2015.
Braun DL, Hampel B, Kouyos R, et al. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men. Clin Infect Dis. 2018 Aug 13. doi: 10.1093/cid/ciy547.）.
Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology. 59: 2403-12. 2014.
Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 33: 106-15. 2000.
Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology.130:1636-1642. 2006.
Bochud P-Y, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 51: 655-6. 2009.
Probst A, Dang T, Bochud M, et al. Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and metaanalysis. J Viral Hepatitis. 18: 745-59. 2011.
Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepatitis. 18: e516-e522. 2011.
Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308: 2584-93. 2012.
Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther. 28: 397-404. 2008.
Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology. 54: 789-800. 2011.
Gane EJ, Hyland RH, An D. et al. Efficacy of Ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology, 149(6):1454-1461. 2015.
Nelson DR, Cooper JN, Lalezari, et al. ALL-oral 12-week treatment with daclatasvir plus sofosbuvir inpatients with hepatitis C virus genotype 3 infection: Ally-3 phase III study. Hepatology;61:1127-1136.2015.
Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 17: 1062-8. 2017.
Wyles D, Poordad F, Wang S, et al. Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial. Hepatology. 67: 514-23. 2018.
Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 67:263-271, 2017.
Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 17:1062-1068, 2017.
Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 67 :1010-7. 2018.
Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 67:1010-1017, 2018.
Izumi N, Takehara T, Chayama K, et sl. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int.12:356-367, 2018.
Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 54:87-95, 2019.
Montes ML, Olveira A, Ahumada A, et al. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. AIDS. 31:1253-60. 2014.
Shafran SD. HIV coinfected have similar SVR rates as HCV mono-infected with DAAs: it's time to end segregation and integrate HIV patients into HCV trials. Clinical infectious diseases. 61: 1127-34. 2015.
Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med. 166:792-8. 2017.
Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 15:132-6. 2017.
Schwabl P, Mandorfer M, Steiner S, et al. Interferon free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther. 45: 139-49. 2017.
Rial-Crestelo D, Sepúlveda M, González-Gasca F, et al. Does fibrosis really regress in HIV/HCV co-infected patients after treatment with direct-antiviral agents? AIDS. 34(3): 427-432. 2020 epub DOI: 10.1097/QAD.0000000000002433.
Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol. 30: 653-9. 1999.
Tanaka H, Tsukuma H, Kasahara A, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer. 87: 741-9. 2000.
Takimoto M, Ohkoshi S, Ichida T, et al. Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients. Dig Dis Sci. 47: 170-6. 2002.
Enokimura N, Shiraki K, Kawakita T, et al. Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C. Anticancer Res. 23: 593-6. 2003.
Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 67:1204-12. 2017.
Merchante N, Rivero-Juarez A, Telletz F, et al. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. J Antimicrob Chemother. 73 :2435-43. 2018.
Salmon-Ceron D, Nahon P, Layese R, et al. HIV/HCV co-infected cirrhotic patients are no longer at higher risk for HCC or end-stage liver disease as compared to HCV mono-infected patients. Hepatology. 2018 Dec 19. doi: 10.1002/hep.30400. [Epub ahead of print]）.
Hasson H, Merli M, Messina E, Bhoori S, Salpietro S, Morsica G, Regalia E, Bagaglio S, Lazzarin A, Uberti-Foppa C, Mazzaferro V. Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. J Hepatol. 67: 415-7. 2017.
Carrieri MP, Protopopescu C, Marcellin F, et al. Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. J Hepatol. 67:1157-67. 2017.
Guardigni V, Toschi A, Badia L, et al.; RECHIV study group. Patients with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for hepatitis C virus. AIDS.35(12):1967-1972.2021.
Spaziante M, Taliani G, Marchetti G, et al. Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study. Viruses. 13(7):1402. 2021.
Ghiglione Y, Polo ML, Urioste A, et al. Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy. Open Forum Infect Dis. 2020 2;7:ofaa115.
Carrero A, Berenguer J, Hontañón V, et al. Effects of Eradication of HCV on Cardiovascular Risk and Preclinical Atherosclerosis in HIV/HCV-Coinfected Patients. J Acquir Immune Defic Syndr. 2020;83:292-300.
Chalouni M, Pol S, Sogni P, et al. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. J Hepatol. 2021;74:37-47.
Auma AWN, Shive C, Damjanovska S, et al. T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy. Open Forum Infect Dis.;8(4):ofab079. 2021.
Lopez Angel CJ, Pham EA, Du H, et al. Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination. Proc Natl Acad Sci U S A. ;118(14): 2021.
Chalouni M, Pol S, Sogni P, et al.; ANRS CO13 HEPAVIH, ANRS CO22 HEPATHER Cohorts Study Groups, Martinez V. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by directacting antivirals: a mediation analysis. HIV Med.22(10):924-935. 2021.
Willis SJ, Kim HN, Achenbach CJ, et al. Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV. HIV Med. 2021 Dec 23. doi: 10.1111/hiv.13218. Epub ahead of print. PMID: 34951105.